Abstract

During acute myocardial infarction (AMI), ischemia leads to necrotic areas surrounded by borderzones of reversibly damaged cardiomyocytes, showing membrane flip-flop. During reperfusion type IIA secretory phospholipase A2 (sPLA2-IIA) induces direct cell-toxicity and facilitates binding of other inflammatory mediators on these cardiomyocytes. Therefore, we hypothesized that the specific sPLA2-IIA inhibitor PX-18 would reduce cardiomyocyte death and infarct size in vivo. Wistar rats were treated with PX-18 starting minutes after reperfusion, and at day 1 and 2 post AMI. After 28 days hearts were analyzed. Furthermore, the effect of PX-18 on membrane flip-flop and apoptosis was investigated in vitro. PX-18 significantly inhibited sPLA2-IIA activity and reduced infarct size (reduction 73 ± 9%, P<0.05), compared to the vehicle-treated group, without impairing wound healing. In vitro, PX-18 significantly reduced reversible membrane flip-flop and apoptosis in cardiomyocytes. However, no sPLA2-IIA activity could be detected, suggesting that PX-18 also exerted a protective effect independent of sPLA2-IIA. In conclusion, PX-18 is a potent therapeutic to reduce infarct size by inhibiting sPLA2-IIA, and possibly also by inhibiting apoptosis of cardiomyocytes in a sPLA2-IIA independent manner.
Introduction

Current acute myocardial infarction (AMI) treatment focuses on reperfusion of the ischemic myocardium. This reperfusion, however, results in the induction of inflammation in the heart, which has been shown to inflict additional damage to the myocardium, hence termed ischemia/reperfusion (I/R)-injury.[1–3] We have previously shown that ischemia not only results in areas of irreversibly damaged cardiomyocytes, but also in border zones of morphologically normal, reversibly damaged cardiomyocytes surrounding these necrotic areas.[4] It can be speculated that inflammation targets these reversibly damaged cardiomyocytes in the border zones of infarction, presumably subsequent to alterations in the plasma membrane. Namely, after AMI, damaged cardiomyocytes lose their membrane phospholipid asymmetry.[5] As a result, the anionic phospholipids phosphatidylserine and phosphatidylethanolamine, which under normal conditions are kept within the inner plasma membrane leaflet, are exposed in the outer membrane leaflet, a process called flip-flop.[6] We and others have shown that this flip-flop can be reversible.[7,8] However, during reperfusion the inflammatory mediator type IIa secretory phospholipase A2 (sPLA2-IIa) was shown to bind to and to induce death in these flip-flopped cardiomyocytes.[4,8,9]

sPLA2-IIa is a 14 kDa acute-phase protein that catalyses the hydrolysis of cellular phospholipids to liberate non-esterified fatty acids.[10] The concomitant formation of lysophospholipids facilitates binding of C-reactive protein (CRP).[11] This binding of CRP then induces binding and activation of complement, resulting in further tissue damage.[12] In addition, sPLA2-IIa can not only induce cell death via CRP and complement activation, but also via a direct cytotoxic effect, independent of other inflammatory mediators.[8] We hypothesized that inhibition of sPLA2-IIa by the specific inhibitor PX-18 [13] might reduce cardiomyocyte death and infarct size in vivo. We further hypothesized that inhibition of sPLA2-IIa would not impair wound healing after AMI, since sPLA2-IIa inhibition would protect the reversibly damaged cardiomyocytes, while the irreversibly damaged cardiomyocytes would still be cleared from the myocardium independent of sPLA2-IIa.[8] In this study, we therefore analyzed the effect of PX-18 on membrane flip-flop (reversibly damaged and/or apoptotic cells), both in vitro and in vivo in a rat AMI model.

Materials and methods

Rat AMI

This study was approved by the VU animal ethics and welfare committee. Female Wistar rats (Harlan Laboratories, Horst, The Netherlands, 240–280 g) were anaesthetized using 3% isoflurane (for initiation, maximal 10 min) and subcutaneous hypnorm/dormicum (fentanyl + fluanisone 0.5 ml/kg, midazolam 5 mg/kg) injection. Rats were ventilated (70 breaths/min, 10–0.5 mbar, Zoovent ventilator, The Netherlands), and heart rate was monitored using Einthoven I ECG.

A left thoracotomy was performed between the fourth and fifth rib, after which a 6.0 ethilon suture was placed around the left anterior descending coronary artery. For the ligation we used a special device that allowed us to pull the suture in one simple movement, reducing the chance of
preconditioning, but also minimalizing the chance of damage to the occluded artery (since the suture cannot cut into the artery). As rats used in the present study were healthy non atherosclerotic rats, no obstruction in the coronary artery was present subsequent to the removal of the ligation, facilitating successful reperfusion. Ischemia was maintained for 40 min, followed by reperfusion. AMI rats were blindly divided into 2 groups, the treatment group (n=17) received the sPLA2-IIA inhibitor PX-18 (kindly provided by RBA Pharma, LLC, Bethesda, Maryland, USA in a formulation by Supratek Pharma Inc, Quebec, Canada), the control group (n=13) received vehicle (NaCl 0.9%). Treatment was given in three daily intravenous doses in the tail vein, (10 mg/kg each) starting directly after reperfusion. 28 days after AMI heart function was analyzed with 2D-echocardiography, using a 13 MHz linear-array transducer (ProSound SSD-4000 PureHD, Aloka, Tokyo, Japan), and rats were sacrificed. Blood was obtained from rats 5 days after AMI. Also sham operated controls were included in this study (n=4).

**Histological staining**

Hearts were cut into five equal slices (Figure 1A), fixed in 4% formaldehyde and embedded in paraffin. Then a phospho-tungstic acid haematoxylin (PTAH)-histological staining was performed on 4µm sections. For this, slides were incubated in Bouin-solution (73% v/v saturated picric acid solution, 25% v/v formaldehyde (37%), 2% v/v glacial acetic acid) at 60 C for 30 min, followed by an incubation in PTAH-solution (0.1% v/v hematoxilin, 1% v/v phosphotungstic acid in distilled water) at 60°C for 60 min. Infarct size, total left-ventricle area and wall-thickness were quantified in the lower 3 slides (Figure 1A) using Q-PRODIT analysis (Leica micro-systems, Cambridge, UK). Slides cut from above the ligature were not analyzed, since no infarcted tissue was found in this area of the heart. In sham operated rats, it was found that suture placement itself caused granulation tissue formation and fibrosis in the suture area of maximal 0.01% of the total left ventricle area. Therefore, in other groups rats with an infarct size <0.01%, were excluded from further analysis (in total two vehicle treated rats).

**Immunohistochemistry**

To analyze inflammatory cells and the putative depositions of sPLA2-IIA in the heart, we performed immunohistochemical stainings, using a rabbit-anti-human MPO antibody (1:500 dilution, DakoCytomation, Eindhoven, The Netherlands), a mouse-anti-rat-CD68 antibody (1:100 dilution, MCA341R Serotec, Kidlington, UK), a mouse- anti-rat ED2 antibody (dilution 1:200, a kind gift from Prof C.D. Dijkstra, Amsterdam, the Netherlands)[14], and a rabbit-anti-human/rat-sPLA2-IIA antibody (1:100 dilution, ab23705, ABCAM, Cambridge, UK). Antigen retrieval was performed using 0.1% pepsin for CD68 and sPLA2-IIA (in 0.02 M HCl, 30 min, 37°C), or by heat activation in Citrate (pH 6) for MPO and ED2. Primary antibodies were incubated for 60 min. For secondary antibody anti-rabbit and anti-mouse EnVision-HRP (DakoCytomation) was used. Staining was visualized using EnVision-diaminobenzidine (DakoCytomation). Control sections were incubated with PBS instead of the primary antibody, and yielded no staining at all (not shown). Numbers of extravascular positive cells were quantified in the entire left ventricle of the cross sections, distinguishing between viable and infarcted areas.
Chapter 2

Cell culture

Neonatal rat cardiomyoblasts (H9c2 cells; ATCC, Manassas, Virginia, USA) were cultured in Dulbecco's Modified Eagles Medium (DMEM; BioWhittaker, Verviers, Belgium) containing 10% Fetal Calf Serum (BioWhittaker), 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-Glutamin (all from Gibco, Paisly, England), in a humidified atmosphere of 5% CO₂ at 37°C. Simvastatin (25 µM, simvastatin-lactone, a gift from Merck & Co., Inc, Rahway NJ, USA), mevalonate (250 µM, Sigma, St. Louis, MO, USA), zVAD-fmk (a pan-caspase inhibitor, 25 µM, zVAD; Alexis Biochemicals, San Diego, CA, USA) and PX-18 (0.2 mg/ml) were all added to the cultures 24h before harvesting. Simvastatin has been shown to induce a significant amount of membrane flip-flop and apoptosis in cardiomyocytes.[15] We therefore used simvastatin to induce (reversible) plasma membrane flip-flop and apoptosis in this study. Simvastatin was activated by dilution (to 1 mM concentration) in 0.1 mol/l NaOH for 30 min prior to incubation. Simvastatin was activated using NaOH, since commercial statins are offered as a lactone form. The activation step by NaOH converts the simvastatin into the more active acid form. As a stock solution, PX-18 was dissolved in PBS containing 10 mM NaOH, pH = 7.4. The final concentration used of PX-18 (0.2 mg/ml) in vitro was comparable to the concentration in blood in vivo.

Membrane flip-flop analysis

Flip-flop in H9c2 cells was analyzed using flow cytometry. For this, cells were collected and stained with annexin V-FITC (1:40 dilution, Bender Med Systems, Vienna, Austria) for 30 min at 37°C in serum-free medium. Propidium iodide was added immediately prior to measurement (PI, 1:40 dilution, Bender Med Systems) and was used to assess membrane permeability, and thus cell death. Cells were analyzed using a FACS-Calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).

Active caspase 3 concentration measurements

Caspase 3 activity in H9c2 cells was determined using a fluorimetric homogeneous caspase assay (Roche, Mannheim, Germany), according to the manufacturer’s instructions. In brief, cells were lysed and incubated with DEVD-rhodamine 110 substrate for 1h at 37°C. Subsequently, the amount of free rhodamine was determined in a microplate fluorescence reader (TECAN spectrafluor, Hombrektikon, Switzerland).

sPLA2-IIA activity measurements

sPLA2-IIA activity was measured in the lysates and culture medium of cells subjected for 24h to simvastatin (25 µM) and/or PX-18 (0.2 mg/ml), and in serum of rats 5 days after AMI, since theoretically then sPLA2-IIA activity is maximal, according to human data.[11] Activity was measured with or without adding of PX-18, according to manufacturer's protocol (Cayman Chemical, Ann Arbor, MI, USA). In brief 10 µl of cell lysate or serum was added to an assay mix containing the substrate diheptanoylphosphatidylcholine, and 5,5-dithio-bis-2-nitrobenzoic acid (DTNB). sPLA2-IIA activity was determined by measuring the release of free thiols in a microplate fluorescence reader (TECAN).
Western blot analysis

H9c2 cells were lysed in lysis-buffer containing 0.001% NP-40, 2.5 mM Tris–HCl, 150 NaCl, and 5 mM EDTA in water. Protein concentration was determined using the BCA protein assay kit (Pierce, Rockford, IL, USA). Then reducing sample loading buffer (0.25 M TRIS pH 6.8, sodium dodecyl sulfate (SDS), glycerol, 2-mercaptoethanol, bromphenol blue) was added and the samples were mixed and heated at 95°C for 5 min. Proteins were subjected to SDS–PAGE, and transferred to nitrocellulose membranes. Membranes were incubated with primary antibodies overnight at 4°C (mouse-anti-rat sPLA2-IIA, 1:250, 2B7/2E7, kindly provided by Dr. CG Schalkwijk, AZM Maastricht, the Netherlands, and b-actin, 1:4,000, BD Biosciences, Franklin Lakes, NJ, USA). Next, membranes were incubated with rabbit-anti-mouse antibody horseradish peroxidase conjugated for 1h at room temperature (DakoCytomation, 1:1,000). Blots were visualised by enhanced chemiluminescence (1:40, ECL; Amersham Bioscience AB, Buckinghamshire, UK), and quantified using a charge couple device camera (Fuji Science Imaging Systems) in combination with AIDA Image Analyzer software (Isotopenmessgeräte; Staubenhardt, Germany).

Statistical analysis

Statistical analysis was performed using GraphPad Prism 4 software. A t-test was performed for two groups and ANOVA was used for more groups, if scores were distributed normally. In case scores were not distributed normally, a Mann–Whitney test or Kruskall–Wallis test was used for analysis. A Pearson chi-square test was used for analysis of discrete values. A P-value smaller than 0.05 was considered to be statistically significant. In the text and figures values are given as mean ± standard error.

Results

PX-18 reduces infarct size and mortality in a rat model of AMI

In sham operated rats, superficial wounds showing fibrosis and granulation tissue formation were induced, but only at the epicardial site of the heart (Figure 1C). In contrast, in rats with AMI areas of fibrosis and/or granulation tissue were found in all areas of the ventricular wall (Figure 1D,E). It has been described recently that PX-18 is a specific sPLA2-IIA inhibitor.[13,16] We validated this inhibitory effect of PX-18 in vivo in the serum of rats 5 days after MI and found that PX-18 indeed significantly reduced sPLA2 activity, namely a reduction of 25% (not shown). Notably, the assay we used could only detect total sPLA2 activity, not sPLA2-IIA activity specifically.

In rats treated with PX-18 infarct size was significantly decreased over 70% when compared to vehicle treated rats, namely from 5.6 ± 2.7% to 1.5 ± 0.5% infarct area/left ventricle area (P<0.05; Figure 1B). Further, we did not find significant differences in wall thickness or immunohistologically in scar tissue formation (amount of fibrosis and granulation tissue) between groups receiving PX-18 or vehicle. Interestingly, all rats treated with PX-18 (n=17) survived after AMI. In contrast, in the vehicle group 3 out of 13 rats died within 2 days after infarction (2 rats during the first day and 1 rat during the second day after AMI), thus during the acute inflammation period (P<0.05).
Figure 1: PX-18 reduces infarct size in a rat model of AMI. A) Schematic overview of rat heart. Hearts were cut into five pieces. Slides were cut from the upper surface of each piece. Only the lower three slides were used for infarct area quantification, since no infarct was found in the slides cut from the area above the ligature. B) Infarct size compared to the vehicle group was decreased with 73 ± 9% in rats receiving PX-18 (P<0.05, one-sided t-test), based on PTAH staining. C,D,E) PTAH staining of the anterior wall of sham operated and vehicle-treated rats. Vital myocardium is stained blue, fibrosis red (arrows). C) Epicardial scar tissue and granulation tissue due to suture placement is visible in sham-operated rat heart (arrow). D,E) Infarcted myocardium (arrows) contains sites of fibrosis (*) and infiltration of inflammatory cells (#). Magnification C,D:12x, E:200x.

We further analyzed putative depositions of sPLA2-IIA in the hearts of rats after AMI. We found expression of sPLA2-IIA on inflammatory cells in the infarcted area 28 days after AMI (Figure 2B). However, sPLA2-IIA expression could not be detected on cardiomyocytes 28 days after AMI (Figure 2A). In contrast, in rats with AMI of 5 days old, derived from another study unrelated to PX-18, sPLA2-IIA was found on jeopardized cardiomyocytes (Figure 2C), which confirms the presumption that sPLA2-IIA is mainly found within the acute inflammation period after AMI.[4,11]
Cardiac output was calculated using parasternal short axis left ventricular systolic and diastolic diameters as has been described, and compared to standard values in the literature of rats of the same weight.[17] In vehicle rats the cardiac output was reduced to 85% (39.6 ± 7 ml/min) of the normal value (46.3 ml/min), whereas in PX-18 treated animals the cardiac output was 97% (45 ± 8 ml/min) of the normal value (P=0.27 PX-18 versus vehicle; Figure 3A). No differences were found in cardiac output between sham operated rats and AMI rats (not shown). In addition, in PX-18 treated rats stroke volume was 15 ± 6% higher compared to vehicle treated rats (PX-18 0.11 ± 0.02 ml versus 0.13 ± 0.02 ml in vehicle treated rats; P=0.10; Figure 3B), however, neither of these parameters differed significantly between the groups.

Figure 2: Immunohistochemical staining of sPLA2-IIA expression in the rat heart after AMI. No sPLA2-IIA expression was found on cardiomyocytes 28 days after AMI in both the vital (A) and the infarcted (B) area. sPLA2-IIA expression was found in inflammatory cells in the infarction area (B, arrows). C) As a positive control, at 5 days post AMI, sPLA2-IIA depositions were found on jeopardized cardiomyocytes in the infarction area in untreated AMI rats (arrows). Magnification: 200x

Figure 3: Effects of PX-18 on heart function. A) Relative cardiac output (CO) was increased from 85 ± 7% to 97 ± 6% of the normal value (46.3 ml/min) in rats receiving PX-18, compared to vehicle-treated rats (P = 0.27, one-sided Mann–Whitney test). B) Stroke volume compared to vehicle-treated rats was increased with 15 ± 6% (P = 0.10, one-sided t-test) in the group receiving PX-18.
Chapter 2

**PX-18 does not affect neutrophilic granulocyte infiltration at 28 days post AMI, but does increase macrophage infiltration**

To investigate the effect of PX-18 on inflammatory cell number, to exclude a possible delay of inflammation by PX-18, we analyzed the presence of neutrophilic granulocytes and macrophages in the infarcted myocardium (infarcted area and borderzone) as well as viable myocardium of the left ventricle (Figure 4). The total amount of neutrophilic granulocytes in the non-infarcted areas of the left ventricle of AMI rats was significantly higher than in the hearts of the sham operated controls (vehicle 0.8 versus 0.1 granulocytes/mm² in sham, P<0.05, Figure 4A). Although we observed a significant number of neutrophilic granulocytes in the infarct, this number of neutrophilic granulocytes at 28 days post AMI is very low when compared to the period short after AMI (unpublished results). No differences in total neutrophilic granulocyte amount were found between the vehicle and PX-18 AMI groups (Figure 4B), suggesting that inflammation was not delayed.

Macrophages were predominantly found in infarcted areas of the heart, with numbers being up to 60 times higher in infarcted myocardium compared to viable myocardium. Furthermore, in viable myocardium macrophages were diffusely solitary present within the tissue, whereas in the infarcted myocardium the macrophages were predominantly found in large conglomerates. The amount of macrophages was significantly increased after treatment with PX-18 compared to vehicle-treated rats, in both the infarction areas (P<0.05) as well as the viable myocardium of the left ventricle (P<0.01, Figure 4C,D). Thus, inhibition of sPLA2-IIA in vivo, using the specific sPLA2-IIA inhibitor PX-18, resulted in a significant reduction of sPLA2-IIA activity in rat serum, a significant reduction of infarct size, a significantly higher survival rate and a significant increase in the amount macrophages compared to vehicle treated rats.

To further investigate the type of macrophages found within the heart, we stained serial slides with a CD68 antibody, which stains all macrophages (Figure 4E) and an ED2 antibody (Figure 4F), which stains resident/late macrophages.[14] The majority of the macrophages in both the vehicle and the PX-18 group stained positive with this ED2 antibody, suggesting that the macrophages found were late type macrophages that promote healing (Figure 4).

**PX18 Decreases membrane flip-flop and apoptosis in rat cardiomyoblasts in vitro independent of sPLA2-IIA**

Since RNA expression of sPLA2-IIA has been shown in cardiomyocytes under conditions of stress,[18,19] we investigated the putative effect of PX-18 on rat cardiomyoblasts in vitro. Previously, we have found that ischemia resulted mainly in an increase in annexin V/PI positive H9C2 cells (late apoptotic/dead cells), whereas the induced number of single-annexin V positive cells (early apoptotic/reversibly damaged) was limited.[8] As the HMG-CoA reductase inhibitor simvastatin has been shown to induce apoptosis and membrane flip-flop in cardiomyocytes,[15] we studied the effect of PX-18 on simvastatin induced (reversible) plasma membrane flip-flop in H9c2 cells and apoptosis.
Figure 4: Effects of PX-18 on neutrophilic granulocyte and macrophage infiltration. Amount of neutrophilic granulocytes (A+B) and macrophages (C+D). A) Amount of neutrophilic granulocytes in the non-infarcted areas of the left ventricle. Significantly more neutrophilic granulocytes were found in infarcted animals, compared to sham operated animals (Kruskal Wallis). B) Amount of neutrophilic granulocytes in the infarcted area of the left ventricle. No significant differences were found between PX-18 treated and untreated animals. C) Amount of macrophages in the non-infarcted areas of the left ventricle. Significantly more macrophages were found in PX-18 treated animals, compared to sham operated and vehicle treated animals (Kruskal Wallis). D) Amount of macrophages in the infarcted area of the left ventricle. Significantly more macrophages were found in PX-18 treated animals, compared to vehicle treated animals (unpaired t-test). * P<0.05, ** P<0.01. E) Immunohistochemical staining for CD68, staining all types of macrophages (arrows). F) Immunohistochemical staining for ED2, staining the late type of macrophages (arrows). Magnification 200x.
Simvastatin (25 µM, 24h incubation) significantly increased the percentage of single-annexin V positive cells to 23 ± 2% compared with 5 ± 1% in control cells (P<0.001; Figure 5A), and decreased the percentage of viable cells (P<0.01). This effect was completely neutralized by mevalonate (6 ± 0% single annexin V positive cells), indicating that the effects induced by simvastatin are indeed the result of its inhibition of HMG-CoA reductase. zVAD (pan-caspase inhibitor) reduced the percentage of single-annexin V-positive cells to 16 ± 6%, however this reduction was not significant (Figure 5B). Furthermore, the percentages of single-annexin V positive cells after treatment with simvastatin and zVAD were still significantly higher than in control cells (P<0.01), indicating that the major part of the simvastatin-induced membrane flip-flop was reversible damaged and not apoptotic.

We next analyzed the effect of PX-18 hereon. We found that PX-18 did not induce an increase in single annexin V positivity of control cells (not subjected to simvastatin), and thus did not have a toxic effect on cells. We further found that PX-18 significantly reduced the percentage of simvastatin induced single-annexin V positive cells from 22 ± 8% to 6 ± 4% (control level 7 ± 5%, P<0.001; Figure 5B). The combination of PX-18 and zVAD did not further reduce the number of annexin V positive cells, when compared to PX-18 alone, indicating that PX-18 inhibits both apoptotic and reversibly flip-flopped cells.

The anti-apoptotic effect of PX-18 was further validated by measuring active caspase 3. Simvastatin indeed significantly increased active caspase 3 concentration with 300 ± 74% compared to control cells (P<0.001). Again it is shown that mevalonate completely neutralized this effect of simvastatin, confirming that the effects induced by simvastatin are the result of its inhibition of HMG-CoA reductase. Caspase-3 activity induced by simvastatin was significantly reduced to 33 ± 14% nM above control level by PX-18 (P<0.001; Figure 5C). The PX-18 treated group did not differ significantly from the control group, nor from the positive control zVAD, indicating that PX-18 protected all apoptotic cells induced by simvastatin. To investigate whether this effect of PX-18 on simvastatin induced membrane flip-flop was sPLA2-IIA mediated, sPLA2-IIA activity was quantified in H9c2 cells and in culture medium of H9c2 cells. However, no sPLA2-IIA activity was detected in untreated H9c2 cells, cells subjected to simvastatin, cells subjected to only PX-18, in cells subjected to PX-18 and simvastatin, nor in the corresponding culture media (not shown). In line with this, sPLA2-IIA expression could not be detected in any of the samples using western blot (Figure 5D). This therefore suggests that the PX-18 inhibitory effect on simvastatin-induced membrane flip-flop and apoptosis was independent of sPLA2-IIA activity.

Figure 5: PX-18 decreases simvastatin induced membrane flip-flop and caspase-3 activity. The effect of PX-18 on simvastatin induced membrane flip-flop and apoptosis. A) Percentages of single-annexin V-positive cells. Cells were subjected for 24h to 25 µmol/l simvastatin or to simvastatin and 250 µmol/l mevalonate. B) Percentages of single-annexin V-positive cells. Cells were incubated ± simvastatin (25 µM) ± PX-18 (0.2 mg/ml) for 24h and/or ± zVAD (25 µM) for 24h. C) Concentrations of active caspase-3 when compared to control cells. Cells were incubated ± simvastatin (25 µM) ± PX-18 (0.2 mg/ml) for 24h and/or ± zVAD (25 µM) and/or ± 250 µmol/l mevalonate for 24h. * P<0.05, ** P<0.01, *** P<0.001. D) sPLA2-IIA is not expressed in H9c2 cells. Western blot analysis of sPLA2-IIA expression in H9c2 cells. Cells were incubated ± simvastatin (25 µM) ± PX-18 (0.2 mg/ml) for 24h. I: sPLA2-IIA expression is only detected in the positive control (serum of rat 5 days after AMI). II: Loading control b-actin is expressed in all samples. ±: Positive control; rat serum 5 days after AMI, C: unstimulated H9c2 cells, S: H9c2 cells with simvastatin; P: H9c2 cells with simvastatin and PX-18.
PX-18 reduces death of cardiomyocytes after AMI
Discussion

In this study, we analyzed the effect of the sPLA2-IIA inhibitor PX-18 on infarct size and heart function in a rat AMI-model, and on membrane flip-flop and apoptosis in cardiomyocytes in vitro. In vivo, treatment with PX-18 significantly reduced sPLA2-IIA activity, infarct size and mortality, without impairing wound healing. In vitro, PX-18 treatment significantly reduced membrane flip-flop, as well as apoptosis in cardiomyocytes, independent of sPLA2-IIA. Previously we have shown that sPLA2-IIA deposits in the heart after AMI in the infarcted areas, where CRP and complement also bind.[4] In addition, sPLA2-IIA was also found to bind to reversibly damaged, flip-flopped cardiomyocytes in the borderzones of infarction, and then induced cell death.[8] This led to the hypothesis that in the heart after AMI, sPLA2-IIA inhibition would result in decreased cardiomyocyte death. We now for the first time show that a specific inhibitor of sPLA2-IIA indeed decreased myocardial infarct size in vivo.

Inhibition of this inflammatory response has been shown to impair wound healing and to induce severe consequences such as wall rupture.[20,21] Importantly, in our study, sPLA2-IIA inhibition by PX-18 did not result in reduced ventricular wall thickness, nor in aneurysmatic infarcts, indicating that wound healing was not impaired. This is in agreement with findings that in the absence of sPLA2-IIA, CRP could still bind to necrotic cardiomyocytes, indicating that necrotic tissue can still be cleared via CRP-complement dependent interactions with phagocytic cells.[2, 8] In addition, we found that PX-18 treatment did not significantly affect the amount of neutrophilic granulocytes in the heart 28 days after AMI, suggesting that neutrophilic granulocyte infiltration was also not delayed. Interestingly, the amount of macrophages in both the infarcted and non-infarcted areas of the heart were significantly increased 28 days after AMI in rats treated with PX-18 compared with vehicle treated rats. It is known that macrophages play an important role in wound healing after AMI. Roles for macrophages in wound healing after AMI are digestion of damaged tissue, promotion of angiogenesis, production of anti-inflammatory mediators, and regulation of extracellular matrix metabolism through synthesis of matrix metalloproteinases and their inhibitors.[22,23] However, several different subtypes of macrophages exist, that may play a different role during inflammation.[24] Nahrendorf et al. [23] have described different roles for these subtypes of macrophages in the early and in the late phase of infarction. They have suggested that early macrophages digest damaged tissue, while late macrophages promote healing. We therefore investigated whether the macrophages we had found in the heart were of this late cell type, by staining with an ED2 antibody.[14] Indeed we found that the majority of macrophages stained positive with this ED2 antibody in the infarcted heart 28 days after AMI, suggesting that these are the late/healing type of macrophages (Figure 4F), indicative for another positive effect of PX-18.

In this study we also found a trend towards increased cardiac output and stroke volume in the PX-18 treated group, compared to the vehicle treated group, although this was not statistically significant. It has been shown that cardiac output is only significantly decreased in large infarcts.[25] Further, heart function parameters were shown to be most improved after treatments of relatively large infarcts.[26,27] In our study, the infarcts were non-aneurysmatic, which could explain its small effect on heart function after AMI and in turn the small effect of PX-18 treatment on the reduced function. We, however, deliberately induced non-aneurysmatic infarcts in a reperfusion model since in patients most infarcts are non-aneurysmatic, because of widespread use of revascularization therapy. In addition we found in a pilot study that complement inhibition most profoundly reduced infarct size in moderately
sized infarcts, rather than in large aneurysmatic infarcts (unpublished results). The effects of the sPLA₂-IIA inhibitor PX-18 on cardiomyocyte flip-flop and apoptosis were further investigated in vitro. Recently, we and others have shown that membrane flip-flop can be a reversible phenomenon, also in cardiomyocytes.[7,28,29] We now found that a significant proportion of the simvastatin induced flip-flopped cardiomyocytes were reversibly damaged cells, whereas another proportion was apoptotic and thus irreversibly damaged. PX18 did prevent apoptosis and membrane flip-flop in reversibly damaged cardiomyocytes independent of sPLA₂-IIA inhibition, as no activity nor expression of sPLA₂-IIA could be detected in the H9c2 cells under the investigated conditions. This is in agreement with previous studies in which mRNA expression, but no protein expression, of sPLA₂-IIA was detected in cardiomyocytes.[18,19].

Figure 6: In vivo mechanisms of cell death during AMI and the effect of sPLA₂-IIA inhibition by PX-18. Ischemia induces reversible and irreversible membrane flip-flop in cardiomyocytes. During the subsequent inflammatory reaction, sPLA₂-IIA binds to flip-flopped membranes and induces cell-death. This results in necrosis of both reversibly as irreversibly damaged cardiomyocytes. PX-18 prevents cell death of reversibly flip-flopped cardiomyocytes by inhibiting flip-flop, by inhibiting direct cytotoxic effects of sPLA₂-IIA, and also by inhibiting sPLA₂-IIA-facilitated binding of CRP and complement. Importantly, irreversibly damaged cardiomyocytes can still be cleared due to binding of CRP independent of sPLA₂-IIA. C: complement, CRP: C-reactive protein, †: cell death, ⊥: inhibition, o: hydrophobic phospholipids (phosphatidylcholine) that in normal cells composes most of the outer leaflet of plasma membranes, •: anionic phospholipids phosphatidylserine (PS) and phosphatidylethanolamine (PE) that are normally kept within the inner leaflet of the plasma membrane.
In this study we thus show several protective roles for PX-18 after AMI as depicted in Figure 6. This figure shows that after AMI reversibly and irreversibly damaged cardiomyocytes are found. Inflammation targets both these type of cells. The reversibly damaged cells are removed due to binding of sPLA2-IIA, and subsequent binding of CRP and complement. The irreversibly damaged cells can also be removed due to direct binding of CRP. PX-18 thus can exert a protective effect on three different levels: (1) PX-18 inhibits membrane flip-flop, and thus the pro-inflammatory state of the plasma membrane. (2) PX-18 inhibits sPLA2-IIA activity, and thus prohibits sPLA2-IIA mediated cell death of at that moment reversibly damaged cardiomyocytes. (3) PX-18 inhibits apoptosis. These results thus show that administration of PX-18 is an effective therapy in reducing post-infarct inflammatory damage to the myocardium, without impairing normal wound healing. These results also show that membrane flip-flop plays a major role in infarct mediated damage of cardiomyocytes, and that therapy targeting this membrane flip-flop is promising.

Acknowledgements: This study was supported by the Institute for CardioVascular Research of the VU University Medical Centre in Amsterdam, the Netherlands (ICaR-VU), project 200380.
References


PX-18 reduces death of cardiomyocytes after AMI


